

Optimizing Initiation for Self-injectable Medications With Remote Demonstration Kits Delivered via Specialty Pharmacy

BACKGROUND

- Patient training for self-injectable medications varies greatly, with some receiving no training or limited resources.
- In-clinic training shows variations in time, methods, and effectiveness
- **Remote Demonstration Kits (RDKs)** with high-fidelity devices are an alternative for at-home self-injection practice.
- Supplying demonstration devices and RDKs to patients for home use via HCPs has been recommended but the logistics may prove challenging.
- Specialty Pharmacy, given its role in supplying self-injectable medications, is well-positioned to provide patient training and distribute RDKs effectively.



OBJECTIVE

- This exploratory pilot attempted to **investigate the impact of supplying self-injection RDK's** (IFU, injection demonstration device and video) to patients via specialty pharmacy.

METHODS

- Patient were randomized equally into two groups: Standard of Care (SoC) or SoC + RDK. The RDK was shipped on the same day as the first dose, and PRO data were collected at intervals, alongside patient refill data from the specialty pharmacy.
- Inclusion Criteria: One of three biologics with a 14-day dosing schedule and naïve to self-injection medication.


MEASURE	MEASURE DESCRIPTION
Script-to-Injection	✓ Patients reported 1 st self-injection
Adherence	✓ Patients claimed 1 st refill
Persistence	✓ Patients who are eligible for 3 dispenses

PATIENT ENGAGEMENT PROGRAM

- **Training Device**- Hands on practice over time to improve patient confidence, motivation, and persistence
- **Digital Support**-Tailored digital experience to engage patients with relevant, timely, and actionable information
- **Real World Evidence Generation**-Access to a data-driven patient journey for analysis, reporting and publication
- **Logistics & Distribution**-Streamlined approach to inventory management, replenishment, and reach-to-patient model

RESULTS

Adherence Impact - PDC (Percentage of Days Covered)




Persistence Impact (Preliminary Findings)

	Persistence Rate*
Control Group (SoC only)	82%
Treatment Group (SoC + RDK)	94%

* Patients discharged due to co-pay and side effects are not included in the persistence calculation

Kit Usages and Perceptions in Treatment Group



CONCLUSIONS

